BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

570 related articles for article (PubMed ID: 21321269)

  • 1. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
    Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET.
    Chen YJ; Rosario BL; Mowrey W; Laymon CM; Lu X; Lopez OL; Klunk WE; Lopresti BJ; Mathis CA; Price JC
    J Nucl Med; 2015 Aug; 56(8):1199-205. PubMed ID: 26045309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
    Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
    Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early 11C-PIB frames and 18F-FDG PET measures are comparable: a study validated in a cohort of AD and FTLD patients.
    Rostomian AH; Madison C; Rabinovici GD; Jagust WJ
    J Nucl Med; 2011 Feb; 52(2):173-9. PubMed ID: 21233181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid-β load predicts medial temporal lobe dysfunction in Alzheimer dementia.
    Frings L; Spehl TS; Weber WA; Hüll M; Meyer PT
    J Nucl Med; 2013 Nov; 54(11):1909-14. PubMed ID: 24101684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.
    Peretti DE; Vállez García D; Reesink FE; van der Goot T; De Deyn PP; de Jong BM; Dierckx RAJO; Boellaard R
    PLoS One; 2019; 14(1):e0211000. PubMed ID: 30653612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid β accumulation assessed with ¹¹C-Pittsburgh compound B PET and postmortem neuropathology.
    Hatsuta H; Takao M; Ishii K; Ishiwata K; Saito Y; Kanemaru K; Arai T; Suhara T; Shimada H; Shinotoh H; Tamaoka A; Murayama S
    Curr Alzheimer Res; 2015; 12(3):278-86. PubMed ID: 25731622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of molecular imaging on the diagnostic process in a memory clinic.
    Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
    Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand.
    Yousefi BH; Manook A; Grimmer T; Arzberger T; von Reutern B; Henriksen G; Drzezga A; Förster S; Schwaiger M; Wester HJ
    ACS Chem Neurosci; 2015 Mar; 6(3):428-37. PubMed ID: 25482310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls.
    Devanand DP; Mikhno A; Pelton GH; Cuasay K; Pradhaban G; Dileep Kumar JS; Upton N; Lai R; Gunn RN; Libri V; Liu X; van Heertum R; Mann JJ; Parsey RV
    J Geriatr Psychiatry Neurol; 2010 Sep; 23(3):185-98. PubMed ID: 20430977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG.
    Carter SF; Schöll M; Almkvist O; Wall A; Engler H; Långström B; Nordberg A
    J Nucl Med; 2012 Jan; 53(1):37-46. PubMed ID: 22213821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET.
    Ossenkoppele R; Tolboom N; Foster-Dingley JC; Adriaanse SF; Boellaard R; Yaqub M; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):990-1000. PubMed ID: 22441582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
    Zhou Y; Resnick SM; Ye W; Fan H; Holt DP; Klunk WE; Mathis CA; Dannals R; Wong DF
    Neuroimage; 2007 Jun; 36(2):298-312. PubMed ID: 17449282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.
    Rowe CC; Pejoska S; Mulligan RS; Jones G; Chan JG; Svensson S; Cselényi Z; Masters CL; Villemagne VL
    J Nucl Med; 2013 Jun; 54(6):880-6. PubMed ID: 23575995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.